62 related articles for article (PubMed ID: 8531125)
1. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.
Chiba M; Nishime JA; Lin JH
J Pharmacol Exp Ther; 1995 Dec; 275(3):1527-34. PubMed ID: 8531125
[TBL] [Abstract][Full Text] [Related]
2. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
4. Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor.
Nishime JA; Wang RW; Lin JH; Chiba M
Drug Metab Dispos; 1999 Sep; 27(9):972-6. PubMed ID: 10460793
[TBL] [Abstract][Full Text] [Related]
5. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
6. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys.
Lin JH; Chiba M; Chen IW; Vastag KJ; Nishime JA; Dorsey BD; Michelson SR; McDaniel SL
J Pharmacol Exp Ther; 1995 Jul; 274(1):264-9. PubMed ID: 7616407
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
Sahali-Sahly Y; Balani SK; Lin JH; Baillie TA
Chem Res Toxicol; 1996 Sep; 9(6):1007-12. PubMed ID: 8870989
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
Grubb MF; Diamond S; Christ DD
Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
Alvarez-Diez TM; Zheng J
Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
[TBL] [Abstract][Full Text] [Related]
11. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation.
Lin JH; Chen IW; Chiba M; Nishime JA; Deluna FA
Drug Metab Dispos; 2000 Apr; 28(4):460-6. PubMed ID: 10725315
[TBL] [Abstract][Full Text] [Related]
12. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.
Iribarne C; Berthou F; Baird S; Dréano Y; Picart D; Bail JP; Beaune P; Ménez JF
Chem Res Toxicol; 1996 Mar; 9(2):365-73. PubMed ID: 8839037
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
14. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1996 Jul; 278(1):21-30. PubMed ID: 8764331
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
Subehan ; Usia T; Kadota S; Tezuka Y
Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
[TBL] [Abstract][Full Text] [Related]
18. Effects of nortriptyline on the activities of human and rat liver microsome bufuralol 1'-hydroxylase in vitro.
Tu ZG; Seddon CE; Boobis AR; Davies DS
Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):465-9. PubMed ID: 2618737
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
Lightning LK; Jones JP; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
Biochemistry; 2000 Apr; 39(15):4276-87. PubMed ID: 10757976
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira M; Suzuki H; Ito K; Sugiyama Y
AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
